

Botanee Biotech (300957 CH)

Headwinds endure

Botanee made a pronounced come-back year-to-date, reviving Tmall GMV from -59.8% YoY to -6.9% YoY between Jan and Oct, and accelerating its quarterly sales growth from 7% in 1Q to 26% in 3Q. Year-to-date shares performance has gone against this trend and, in our view, the free-fall is running ahead of consensus estimates which still looked rather reserved in pricing-in the ongoing dilemma that Botanee is facing. These are threefold: 1) when macro headwinds such as consumption trade-down (see our [thematic report](#)) and low fertility wish linger (see our [Feihe downgrade report](#)), growth outlook among AOXMED (super high-end) and Winona Baby could normalise sooner than expected, and Botanee's single-brand risk could be exposed further given a full-fledged close-quarters competition among brands; 2) herbal-/HA-based functional skincare is incrementally crowded out by the collagen-based. While Botanee's portfolio remains largely herbal-based, we also see uncertainties residing with its collagen debuts, amid a languishing consumption sentiment, which offer lower efficacy (homology level) relative to peers; 3) the top-line-accretive buy-out of Yuejiang could ironically be margin-dilutive considering a higher sales contribution from colour make-up, and the late migration of P&M to live-streaming might not be as rewarding when the low-hanging fruit is gone. Albeit transient, these concerns could put Botanee in the doldrums until we are given any tangible roadmap that substantiates a turn-around. While we are still cautiously optimistic and are looking for a 7.6% broad-base cosmetics sales growth for 2024E (in line with TSR), we recommend Proya (603605 CH, BUY) and [Giant Biogene](#) (2367 HK, BUY, covered by our Healthcare team) which possess solid brand/technology moats. We downgrade Botanee to HOLD, and expect the shares to generate market-performing return in the next 12 months.

- **Major earnings assumptions.** To Botanee, headwinds above could financially morph into decelerated organic top-line growth (14.5% CAGR between 2022-25E), mix-diluted gross margins (an average 0.2pp decline p.a.) and a persistently inflated promotional expense (+1.2pp in selling expense-to-revenue ratio). These in aggregate prompt us to trim our 2023-25E net earnings by 19-22%, and put us 12-16% below consensus. Our forecasts include the takeover impact of Yuejiang.
- **Valuation.** Botanee has wrapped up its upcycle with ~50% YoY sales growth per annum. To bake in a normalising growth expectation, we rebase our long-term average starting from 3Q22 (from previously since IPO). Our revised TP is based on 31.0x (from previously 48.5x) end-23E P/E, which still represents -1sd below the average.

Earnings Summary

(YE 31 Dec)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue (RMB mn)	4,022	5,014	5,905	7,444	8,466
YoY growth (%)	52.6	24.6	17.8	26.1	13.7
Net profit (RMB mn)	863.5	1,051.2	1,114.8	1,337.8	1,655.0
YoY growth (%)	58.8	21.7	6.0	20.0	23.7
Consensus EPS (RMB)	na	na	2.99	3.72	4.61
P/E (x)	105.1	69.9	28.1	23.4	18.9
P/B (x)	19.0	13.1	4.9	4.2	3.6
Yield (%)	0.3	0.5	1.1	1.4	1.7
ROE (%)	28.9	20.3	18.6	19.4	20.7
Net gearing (%)	Net cash	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIGM estimates

HOLD (Down)

Target Price RMB 81.6
 (Previous TP RMB157.0)
Up/Downside 11.6%
Current Price RMB 73.1

China Consumer

Joseph WONG
 (852) 3900 0838
 josephwong@cmbi.com.hk

Bella Li
 (852) 3757 6202
 bellali@cmbi.com.hk

China Healthcare

Jill WU, CFA
 (852) 3900 0842
 jillwu@cmbi.com.hk

Cathy WANG
 (852) 3916 1729
 cathywang@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	31,329.5
Avg 3 mths t/o (RMB mn)	243.9
52w High/Low (RMB)	152.23/72.28
Total Issued Shares (mn)	423.6

Source: FactSet

Shareholding Structure

Kunming Nona Technology Co., LTD	46.1%
Tianjin Sequoia Juye Equity Investment P	14.6%


Source: SZSE

Share Performance

	Absolute	Relative
1-mth	-16.6%	-18.0%
3-mth	-23.5%	-18.9%
6-mth	-26.7%	-19.0%

Source: FactSet

12-mth Price Performance




Source: FactSet

Embracing the new normal


- Cosmetics may no longer take shares within a more rationalised consumer wallet.** Low penetration and channel migration to e-commerce platforms enabled cosmetics sales to grow at a 60%+ CAGR between 2019 and 2021, consistently tracking above the 40%+ in total social retail sales (TSR). The expansion cycle was staged: it began with the steady growth between 2016 and 2018, followed by a persistent beat between 2019 and mid-22, and plateaued again until now. The driving forces behind the scene are two-fold, such as the dissipating low-hanging fruit of live-streaming, and languishing spending power in the post-pandemic era. In our view, these trends are here to stay, and when consumers are becoming more value-cautious and ingredient-savvy, and when they are incrementally re-prioritizing their wallet shares, higher price tags have made skincare (relative to colour make-up) more vulnerable to trade-down (though selective and transient). We caveat that a lower 2023 could just be the start, or essentially the inflection point, of the renewed cycle with cosmetic sales growth re-converging to that of TSR.

Figure 1: China GDP and TSR growth trends




Source: Wind, CMBIGM

Figure 2: TSR and cosmetic sales growth trend




Source: Wind, CMBIGM

Figure 3: Cosmetics sales to TSR



Source: Wind, CMBIGM


Figure 4: Skincare spending to total cosmetics



Source: Wind, CMBIGM


- **Single-brand risk could further be exposed.** To Botanee, AOXMED and Winona Baby are two emerging brands in the high-end and babycare segments. With the concerns we highlighted, these brands could see sooner-than-expected normalisation, and derail from its high-growth trajectory, in particular without tailwinds from a favourable comps. We envisage that brand diversification would not bear fruit in the near term, and Winona would remain the major brand to Botanee with +90% revenue contribution.

Figure 5: Winona Baby's online sales on Tmall/Taobao normalizing on a YoY high base




Source: Moojing, CMBIGM

Figure 6: Winona Baby's monthly sales growth across three platforms



Source: Moojing, CMBIGM

Figure 7: Winona contributes more than 95% of Botanee's total GMV




Source: Moojing, CMBIGM


Close-quarters combat among brands across the "4P"

- **Consumer trade-up may not be as eye-catching.** Premiumization and polarization is selectively happening within the cosmetics sector. We argued that domestic brands were collectively catching up and taking market shares from foreign brands. But now, we notice the situation is slightly twisted, with demand polarization becoming more obvious. Year-to-date data may not be conclusive, but indeed alarming enough to raise the eyebrows – the top 15 brands, mainly high-end/prestige brands we surveyed on Tmall/Taobao have been losing market shares (likely to long-tail brands) compared to the last two years. This comes in with an exception in Proya, Skinceuticals and Freeplus. The latter two position themselves as niche functional skincare brands and ride on the popularity of HA and canarium album extract essences, Nicotinamide and aminoamides face washes.


- **Competition heated up in all of the “4P”.** The fatigue among consumers’ online cosmetics buying over the 3-year lockdown has lured brands into price cuts in an attempt to snap up/maintain their competitiveness. Of note, between 2021 and 9M23, online cosmetics prices were 5.3% lower than offline. Estee Lauder again is the major loser as the company looks likely to have over-shipped since the beginning of this year upon a softer-than-expected recovery. Beyond price cuts, brands are also increasing their marketing spend to re-establish their brand equity. Witnessing this, we argue that competition has fully heated up across the “4P”, from previously Place (e-commerce migration) to currently Price (deeper discounts), Promotion (higher ad spend) and Product (ingredient heterogeneity).

Figure 8: Market share trends on Tmall/Taobao


Source: Moojing, CMBIGM estimates

Figure 9: ASP trends on Tmall/Taobao

Source: Moojing, CMBIGM estimates

Figure 10: Brands increase advertising spend

Source: Company data, CMBIGM estimates

Figure 11: Brands' GMV growth on Tmall/Taobao

Source: Moojing, CMBIGM

- **Uncertainties remained with Botanee's collagen-based debut.** Botanee have introduced collagen-based SKUs since 2021 and is now listing two collagen-based SKUs on Winona's Tmall flagship store. Compared with the 'humanized collagen (重组人源化胶原蛋白)' R&D techniques of Giant Biogene, Shanxi Jinbo, Trauer and Voolga, Botanee's 'collagen-like protein (重组类胶原蛋白)', which involves amino acid sequence redesign and modification, offers lower biocompatibility and collagen efficacy.

Figure 12: Winona's products has lower homology level than those offered by peers


	Winona		Comfy			Voolga
Main ingredient	Collagen solution		Type I & III Humanized Collagen concentrate			Type III Humanized Collagen concentrate
Ingredient homology level to human	80% +		100%			100%
Product type	Dressing	Spray	Dressing	Spray	Emulsion	Dressing
Price (RMB)	188 / 6 pcs	139 / 50 ml	187 / 5 pcs	198 / 100 ml	268 / 80 g	134 / 5 pcs
Tmall sales vol. of previous 365 days	10 k+	5 k+	400 k+	30 k+	9 k+	10 k+

Source: Tmall, CMBIGM

The shift from herbal-/HA-based to collagen-based skincare

- **Collagen-based skincare commensurate better with “medical beauty”.** Surveys by Frost and Sullivan have unveiled that a growing demand for rapid skin barrier repair with consumers who have undertaken non-surgical medical aesthetics procedures, with the latter likely to deliver 54% stack growth between 2020 and 2025E. Recombinant collagen is seen as the best active ingredient, among animal-derived collagen and hydraulic acid, to relieve post-procedure adverse reaction such as redness, itch, scaling and dryness. Our data collected from Moojing substantiate the trend, with plant-based brands (such as Caudalie, Herborist, Inoherb)/hydraulic acid-based brands (such as Voolga) grew at a 9-16%/29% CAGR between 2020 and October 2023, underperforming Comfy (Giant Biogene) that saw a 91% CAGR.

Figure 13: GMV growth vs market size among brands on Taobao/Tmall




Source: Moojing, CMBIGM

- **Consumers are becoming more ingredient-savvy.** Statistics from BEBD show that user time spend on active viewing of skincare products' ingredients increased by 177% YoY in 2021, and that on actively researching for the functionalities of specific ingredients increased by 111% YoY. Meanwhile, consumers with skin concerns have undergone a significant shift in their pursuits from stabilizing skin conditions towards repair and rejuvenation efficacy. Search frequency for herbal ingredients among various online surveys in 2022 have shown a significant downtrend vs that in 2020. About half of the searches associated with skincare were related to anti-oxidation and anti-aging.


Figure 14: Significant reshuffle of active ingredients searched for skincare SKUs

2020	2022
Top 1 Centella asiatica extract (积雪草)	Nicotinamide (烟酰胺)
Top 2 Selaginella tamariscina extract (复活草)	Hyaluronic acid (透明质酸钠)
Top 3 Laminaria extract (海藻)	Tocopherol (生育酚)
Top 4 Chamomile extract (洋甘菊)	Centella asiatica extract (积雪草提取物)
Top 5 Aloe extract (芦荟)	Glabridin extract (光果甘草根提取物)

Source: Beautydata, BEBD, CMBIGM

Figure 15: Online search frequency changes on active ingredients 2022

Source: BEBD, CMBIGM

Figure 16: About half of skincare searches are associated with anti-oxidation/aging

Source: BEBD, CMBIGM

- **Foreign brands are joining the party.** Meanwhile, the participation of foreign brands, notably with more proven technology and hence product quality, has speeded up the shift. Comparing the price range and active ingredient of the 4 SKUs below, La Roche Posay looks to be the most value-for-money brand and has every reason to sell better than its peers. A more proactive use of social media also aids foreign brands to establish more localised touch points for client acquisition.

Figure 17: Foreign brands offer equally high value-for-money SKUs to local brands

Brand	Country	Product name	11.11 price on Tmall	Sales vol. in the past 365 days	Ingredients category
La Roche Posay	France	Cicaplast Baume B5 cream	80 / 40 ml	500 k +	Bioactive
Avene	France	Cicalfate cream	68 / 40 ml	80 k +	Bioactive
Cetaphill	France	Smoothing & Comforting facial cream	130 / 45 ml	100 k +	Bioactive
Winona	China	Tolerance Extreme cream	168 / 50 g	400 k +	Plant based
Grain Rain	China	Whitening Restore cream	168 / 130 g	300 k +	Plant based



Source: Tmall, CMBIGM

Figure 18: Foreign brands are turning more proactive in social media

	No. of posts on Red			No. of fans on Red		
	Jul 2021	Nov 2023	Chg.	Jul 2021	Nov 2023	Chg.
Winona	60 k+	186 k+	210%	131 k+	187 k+	43%
Dr. YU	20 k+	60 k+	200%	23 k+	56 k+	143%
Skinceuticals	80 k+	300 k+	275%	66 k+	111 k+	68%
La Roche Posay	110 k+	192 k+	75%	109 k+	146 k+	34%
Vichy	30 k+	31 k+	3%	61 k+	67 k+	10%
CeraVe		58 k+			29 k+	
Cetaphil		55 k+			36 k+	

Source: CMBIGM

A closer look on the Yuejiang takeover

- Botanee announced the acquisition of a 51% stake in Yuejiang Investment Co with RMB535.5mn after Sep 28 market close, funded by internal cash. The takeover agreement also specified that Yuejiang would have to achieve net profits of RMB50mn/80mn/105mn over 2023/24/25E.
- Yuejiang owns two brands, i.e., Za and Pure&Mild. Za is a colour make-up brand, while P&M offers plant-based functional skincare products. Both are positioned as mass-market brands with flagship products set at the RMB70-100 price range.
 - Za was established in 1997 with a focus on 20-30 aged Asia women. Whitening primer has been the brand's flagship product, and the remaining core products including primer, sunscreen, and essence are whitening focused.
 - P&M was founded in 2021. Yuejiang acquired it from Shiseido who established the brand as a localisation initiative to cater to skincare needs in China. P&M had its golden era about 10 years ago with as many as 8,000 distribution outlets, but experienced a slowdown with the entry of Korean brands and the rise of local brands.
- Financially, Yuejiang achieved revenue/net profits of RMB308mn/14.3mn in 2022, and RMB409mn/29mn in 1H23. The company derived 80% of its sales online, among which 60% of the GMV came from online 3rd-party marketplace platforms like Tmall, JD and Vipshop, and the remaining from live-streaming. For its brick-and-mortar channels, Yuejiang leverages KAs such as Watsons, and counters in department stores.

Figure 19: Limited financial impact to Botanee

(RMB mn)	2022	9M23	2023E	2024E	2025E
Yuejiang					
Revenue	308	409			
NP	14	29	50	80	105
NPM	4.6%	7.1%			
Botanee					
Revenue	5,014	3,431	5,905	7,444	8,466
NP	1,051	579	1,115	1,338	1,655
NPM	21.0%	16.9%	18.9%	18.0%	19.5%
Impact to Botanee			2.3%	3.0%	3.2%
Shareholding			51.0%	51.0%	51.0%

Source: SZEx, CMBIGM

Figure 20: Yuejiang's GMV breakdown

(RMB mn)	TB&Tmall	JD	Douyin
2022			
Za	153	47	47
Pure & Mild	46	15	2
Total GMV	199	63	49
1H23			
Za	96	46.693	105
Pure & Mild	14	6	2
Total GMV	110	53	107

Source: SZEx, CMBIGM

Figure 21: P&M price promotion on Tmall



Source: Tmall, CMBIGM

Earnings change and valuation

- **Major earnings assumptions.** To Botanee, headwinds we discussed could financially morph into decelerated organic top-line growth (14.5% CAGR during 2022-25E), mix-diluted gross margins (an average 0.2pp decline p.a.) and a persistently inflated promotional expense (+1.2pp in selling expense-to-revenue ratio). These in aggregate prompt us to trim our 2023-25E net earnings by 19%-22%, and put us 12%-16% below consensus.

Figure 22: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	5,905	7,444	8,466	6,547	8,429	NA	-9.8%	-11.7%	NA
Gross Profit	4,420	5,521	6,276	4,915	6,308	NA	-10.1%	-12.5%	NA
EBITDA	1,205	1,525	1,964	1,522	1,989	NA	-20.9%	-23.3%	NA
Net profit	1,115	1,338	1,655	1,374	1,716	NA	-18.9%	-22.0%	NA
Gross Margin	74.8%	74.2%	74.1%	75.1%	74.8%	NA	-0.2ppt	-0.7ppt	NA
EBITDA Margin	20.4%	20.5%	23.2%	23.2%	23.6%	NA	-2.8ppt	-3.1ppt	NA
Net Margin	18.9%	18.0%	19.5%	21.0%	20.4%	NA	-2.1ppt	-2.4ppt	NA

Source: CMBIGM estimates


Figure 23: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	5,905	7,444	8,466	6,254	7,852	9,592	-5.6%	-5.2%	-11.7%
Gross Profit	4,420	5,521	6,276	4,734	5,957	7,280	-6.6%	-7.3%	-13.8%
EBITDA	1,205	1,525	1,964	1,428	1,809	2,265	-15.6%	-15.7%	-13.3%
Net profit	1,115	1,338	1,655	1,268	1,588	1,965	-12.1%	-15.8%	-15.8%
Gross Margin	74.8%	74.2%	74.1%	75.7%	75.9%	75.9%	-0.9ppt	-1.7ppt	-1.8ppt
EBITDA Margin	20.4%	20.5%	23.2%	22.8%	23.0%	23.6%	-2.4ppt	-2.6ppt	-0.4ppt
Net Margin	18.9%	18.0%	19.5%	20.3%	20.2%	20.5%	-1.4ppt	-2.3ppt	-0.9ppt

Source: Bloomberg, CMBIGM estimates


- **Valuation.** In our view, Botanee has wrapped up its high-growth cycle (~50% YoY sales growth). To bake in a normalising growth expectation, we rebase our long-term average starting from 3Q22 (from previously since IPO). Our revised TP is based on 31.0x (from previously 48.5x) end-23E P/E, which still represents -1sd below the average.

Figure 24: 12M forward P/E band



Source: Company data, Bloomberg, CMBIGM estimates

Figure 25: 12M trailing P/B band



Source: Company data, Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Revenue	2,636	4,022	5,014	5,905	7,444	8,466
Cost of goods sold	(626)	(965)	(1,243)	(1,485)	(1,922)	(2,190)
Gross profit	2,010	3,057	3,771	4,420	5,521	6,276
Operating expenses	(1,385)	(2,092)	(2,702)	(3,307)	(4,168)	(4,572)
Selling expense	(1,107)	(1,681)	(2,048)	(2,539)	(3,201)	(3,471)
Admin expense	(169)	(245)	(343)	(402)	(506)	(576)
R&D expense	(63)	(113)	(255)	(300)	(378)	(430)
Others	(46)	(52)	(56)	(66)	(83)	(95)
EBITDA	650	1,000	1,130	1,205	1,525	1,964
Depreciation	10	14	26	47	118	196
Other amortisation	14	21	35	44	54	64
EBIT	625	966	1,069	1,113	1,353	1,704
Net Interest income/(expense)	1	11	16	16	16	16
Other income/expense	22	42	129	129	129	129
Pre-tax profit	648	1,018	1,214	1,258	1,498	1,849
Income tax	(104)	(154)	(163)	(169)	(202)	(249)
Minority interest	0	1	(1)	(26)	(42)	(55)
Net profit	544	863	1,051	1,115	1,338	1,655
Gross dividends	163	254	339	359	431	533

BALANCE SHEET	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Current assets	1,391	5,225	5,715	5,704	6,439	7,255
Cash & equivalents	752	2,035	2,514	2,365	2,823	3,463
Account receivables	187	247	270	286	340	386
Inventories	254	463	671	793	1,016	1,146
Prepayment	29	46	42	42	42	42
Other current assets	169	2,433	2,218	2,218	2,218	2,218
Non-current assets	211	587	1,004	1,875	2,249	2,739
PP&E	69	113	206	512	852	1,309
Deferred income tax	13	16	51	51	51	51
Investment in JVs & assos	0	0	0	536	536	536
Intangibles	55	65	78	89	101	112
Other non-current assets	74	395	668	687	709	731
Total assets	1,602	5,812	6,719	7,579	8,688	9,994
Current liabilities	391	900	992	1,060	1,185	1,264
Short-term borrowings	0	0	0	0	0	0
Account payables	135	362	372	441	565	644
Tax payable	80	122	119	119	119	119
Other current liabilities	139	345	442	442	442	442
Contract liabilities	37	71	58	58	58	58
Non-current liabilities	9	134	125	125	125	125
Long-term borrowings	0	50	11	11	11	11
Deferred income	7	6	56	56	56	56
Other non-current liabilities	1	78	59	59	59	59
Total liabilities	400	1,034	1,117	1,185	1,310	1,389
Share capital	473	579	635	635	635	635
Retained earnings	726	1,330	2,072	2,837	3,780	4,953
Other reserves	0	2,846	2,871	2,871	2,871	2,871
Total shareholders equity	1,202	4,778	5,602	6,394	7,378	8,606
Minority interest	3	23	24	50	92	147
Total equity and liabilities	1,602	5,812	6,719	7,579	8,688	9,994

CASH FLOW	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	648	1,018	1,214	1,258	1,498	1,849
Depreciation & amortization	25	35	61	92	172	260
Tax paid	(104)	(154)	(163)	(169)	(202)	(249)
Change in working capital	(151)	13	(413)	(43)	(111)	(43)
Others	13	240	71	26	42	55
Net cash from operations	431	1,153	769	1,163	1,399	1,872
Investing						
Capital expenditure	(89)	(271)	(353)	(428)	(546)	(750)
Acquisition of subsidiaries/ investments	(760)	(8,628)	(6,809)	0	0	0
Others	763	6,341	7,144	(536)	0	0
Net cash from investing	(86)	(2,558)	(18)	(963)	(546)	(750)
Financing						
Dividend paid	(104)	(191)	(255)	(349)	(395)	(482)
Net borrowings	(15)	0	0	0	0	0
Others	(2)	2,855	(65)	0	0	0
Net cash from financing	(121)	2,664	(320)	(349)	(395)	(482)
Net change in cash						
Cash at the beginning of the year	527	776	2,083	2,514	2,365	2,823
Exchange difference	0	(0)	0	0	0	0
Others	1	0	0	0	0	0
Cash at the end of the year	752	2,035	2,514	2,365	2,823	3,463
GROWTH	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec						
Revenue	35.6%	52.6%	24.6%	17.8%	26.1%	13.7%
Gross profit	28.9%	52.1%	23.3%	17.2%	24.9%	13.7%
EBITDA	27.3%	53.9%	13.0%	6.6%	26.6%	28.8%
EBIT	27.6%	54.5%	10.7%	4.1%	21.6%	26.0%
Net profit	32.0%	58.8%	21.7%	6.0%	20.0%	23.7%
PROFITABILITY	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec						
Gross profit margin	76.3%	76.0%	75.2%	74.8%	74.2%	74.1%
EBITDA margin	24.7%	24.9%	22.5%	20.4%	20.5%	23.2%
Return on equity (ROE)	55.4%	28.9%	20.3%	18.6%	19.4%	20.7%
GEARING/LIQUIDITY/ACTIVITIES	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec						
Net debt to equity (x)	(0.6)	(0.4)	(0.4)	(0.4)	(0.4)	(0.4)
Current ratio (x)	3.6	5.8	5.8	5.4	5.4	5.7
Receivable turnover days	20.7	19.7	18.8	17.2	15.3	15.7
Inventory turnover days	131.9	135.6	166.5	179.9	171.8	180.2
Payable turnover days	65.1	93.9	107.8	99.9	95.5	100.8
VALUATION	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec						
P/E	na	105.1	69.9	28.1	23.4	18.9
P/E (diluted)	na	105.1	69.9	28.1	23.4	18.9
P/B	na	19.0	13.1	4.9	4.2	3.6
Div yield (%)	na	0.3	0.5	1.1	1.4	1.7

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong. Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.